NCT02178488 (D-STAPH) is a Phase 2 clinical trial of Cholecalciferol in Methicillin Resistant Staphylococcus Aureus, sponsored by Peter Bergman.

Who is sponsoring NCT02178488?

NCT02178488 is sponsored by Peter Bergman.

What drugs are being tested in NCT02178488?

Interventions in NCT02178488: Cholecalciferol, Placebo.

Is NCT02178488 still recruiting?

NCT02178488 is currently completed. Last updated 21 January 2018.

Last reviewed 2018-01-21 · How we verify

NCT02178488: D-STAPH

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Vitamin D Supplementation to Persistent Carriers of MRSA - A Double Blind, Randomised Controlled Trial

Completed Phase 2 Last updated 21 January 2018

What this trial tests

Phase 2 trial testing Cholecalciferol in Methicillin Resistant Staphylococcus Aureus in 60 participants. Completed in 1 December 2017.

Timeline

1 December 2014

Primary endpoint
1 December 2017

1 December 2017

Quick facts

Lead sponsor	Peter Bergman
Phase	Phase 2
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	quadruple
Primary purpose	treatment
Enrollment	60
Start date	1 December 2014
Primary completion	1 December 2017
Estimated completion	1 December 2017
Sites	2 locations across Sweden

Drugs / interventions tested

Cholecalciferol (cholecalciferol) — full drug profile →
Placebo

Conditions studied

Methicillin Resistant Staphylococcus Aureus — all drugs for Methicillin Resistant Staphylococcus Aureus →
Vitamin D3 Deficiency — all drugs for Vitamin D3 Deficiency →

Sponsor

Peter Bergman

Who can join

Adults 18 to 75, any sex, with Methicillin Resistant Staphylococcus Aureus or Vitamin D3 Deficiency. Patients with the condition only — healthy volunteers not accepted.

What's being measured

Primary outcomes are the specific endpoints the trial is designed to prove or disprove.

MRSA
Time frame: Baseline, 3, 6, 9 and 12 months
The primary endpoint is the decline of MRSA-positive patients during a 12-month period in the treatment groups (vitamin D/Placebo) based on 5 measurements with 3 months interval.

Sponsor's own description

The purpose of this study is to treat persistent MRSA carriers with vitamin D supplementation during a 12 month to see if the number of MRSA positive patients can be reduced.

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

Vitamin D binding protein is not affected by high-dose vitamin D supplementation: a post hoc analysis of a randomised, placebo-controlled study.
Björkhem-Bergman L, Torefalk E, Ekström L, Bergman P. · · 2018 · cited 18× · PMID 30157946 · DOI 10.1186/s13104-018-3725-7
Vitamin D supplementation to persistent carriers of MRSA-a randomized and placebo-controlled clinical trial.
Björkhem-Bergman L, Missailidis C, Karlsson-Valik J, Tammelin A, et al · · 2018 · cited 7× · PMID 29931657 · DOI 10.1007/s10096-018-3306-7

Verify or expand the search:

Other trials of Cholecalciferol

Trials testing the same drug.

NCT06847373 — Efficacy and Safety of Vitamin D Supplementation in Pediatric Patients with Obesity · NA · recruiting
NCT06447441 — Clinical Outcomes Of Mega-dosage Supplementations Of Cholecalciferol In Critically Ill Patients With Sepsis · NA · not yet recruiting
NCT06301178 — Effect of Vitamin D Injection on Hypertrophic Scars and Keloids · Phase 1, PHASE2 · completed
NCT06053281 — The Role of Vitamin D in Neuroinflammatory on Drug Resistant Epilepsy · EARLY_PHASE1 · unknown
NCT05860270 — Oral Vitamin D Supplementation Prevent Peritoneal Dialysis-related Peritonitis · Phase 4 · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT02178488 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Peter Bergman
Last refreshed: 21 January 2018

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02178488.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing